Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination drug** comprising two distinct components: **phleum pratense grass pollen allergen extract** and **desloratadine**. - **Phleum pratense grass pollen allergen extract** is an allergenic extract derived from Timothy grass pollen, commonly used as immunotherapy for the treatment of grass pollen-induced allergic rhinitis and conjunctivitis[1][7]. The mechanism involves administration of controlled allergen doses to induce tolerance by promoting immune modulation, typically increasing IgG antibodies and blunting the seasonal rise of IgE, and reducing hypersensitivity responses[8]. - **Desloratadine** is a second-generation antihistamine that acts as an antagonist at the histamine H1 receptor, blocking histamine-mediated allergic symptoms such as sneezing, itching, and runny nose. It does not cross the blood–brain barrier readily and is less sedating than first-generation antihistamines. The combination is intended for patients suffering from seasonal allergic rhinitis/hay fever due to grass pollen, providing both allergen-specific immunotherapy (disease-modifying) and immediate symptomatic relief[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phleum pratense grass pollen allergen extract + desloratadine.